Institute for Clinical & Economic Review Publishes Evidence Report on Therapies for Hemophilia A
October 17, 2020
October 17, 2020
BOSTON, Massachusetts, Oct. 17 (TNSRep) -- The Institute for Clinical and Economic Review issued the following announcement on Oct. 16:
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech) for the treatment of hemophilia A. In August 2020, BioMarin received a Complete Response Lett . . .
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech) for the treatment of hemophilia A. In August 2020, BioMarin received a Complete Response Lett . . .